Differential expression of cGMP-inhibited cyclic nucleotide phosphodiesterases in human hepatoma cell lines  by Murata, Taku et al.
FEBS 17021 FEBS Letters 390 (1996) 29-33 
Differential expression of cGMP-inhibited cyclic nucleotide 
phosphodiesterases in human hepatoma cell lines 
Taku Murata, Masato Taira, Vincent C. Manganiello* 
Pulmonary~Critical Care Medicine Branch, NHLB1, NIH, Bethesda, MD 20892, USA 
Received 27 February 1996; revised version received 9April 1996 
Abstract PDE3 or cGMP-inhibited cyclic nucleotide phospho- 
diesterase (cGI PDE) activity was detected in homogenates of 
HepG2, Hep3B and HUH7, but not SK-Hep-1, human hepatoma 
cells. In HepG2 and Hep3B cells PDE3 activity was found 
predominantly in particulate fractions; in HUH7, in both 
particulate and supernatant fractions, cDNAs encoding two 
human PDE3s (an 'adipocyte' type, HcGIP1, and a 'cardiovas- 
cular' type, HcGIP2) have been cloned. HcGIP1 cDNA 
hybridized strongly with poly(A) + RNA species from HepG2 
and Hep3B. Both HcGIP1 and HcGIP2 mRNAs were expressed 
in Hep3B and HuH7 cells. The nucleotide sequence of an ~ 300- 
bp cDNA fragment, isolated after RT-PCR cloning from HepG2 
RNA, was identical to a sequence within the conserved omain of 
HcGIP1 cDNA, consistent with the presence of HcGIP1 mRNA 
in HepG2 cells. 
Key words: Human hepatoma cell line; PDE3 or cGMP- 
inhibited cyclic nucleotide phosphodiesterase; PDE4 or 
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1. Introduction 
Seven cyclic nucleotide phosphodiesterase (PDE) gene fam- 
ilies have been identified [1-5]. The PDE3 or cGMP-inhibited 
(cGI) PDE family is characterized by a high affinity for cAMP 
and cGMP (with Vm~x greater for cAMP than for cGMP) and 
competitive inhibition of its cAMP hydrolytic activity by 
cGMP, cilostamide (OPC 3689) and certain positive inotropic 
agents, including milrinone and enoximone [6]. PDE3s have 
been purified from adipose and cardiac tissues, rat liver, bo- 
vine aortic smooth muscle and human platelets [6-13]. Studies 
with specific PDE3 inhibitors suggest hat PDE3s regulate 
cAMP pools important in myocardial contractility, platelet 
aggregation, vascular smooth muscle relaxation, lipolysis 
and vascular smooth muscle and T-lymphocyte proliferation 
[1-6,14-19]. cDNAs encoding two distinct but related PDE3 
isoforms (cGIPI and cGIP2) have been cloned from rat (R) 
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The HcGIP1 (or HSPDE3B) cDNA sequence has been submitted to 
Genbank, Accession 438178. 
and human (H) adipose and human (H) cardiac cDNA and 
genomic libraries ([20,21]; unpublished observations), cGIP1 
and cGIP2 isoforms are products of two different genes, lo- 
cated on human chromosomes 11and 12, respectively (unpub- 
lished observations). Their deduced primary amino acid se- 
quences indicate that the C-terminal regions of PDE3s 
contain the catalytic domain conserved among all mammalian 
PDEs and that rat and human cGIP1 (or cGIP2) are more 
closely related than cGIP1 and cGIP2 from the same (rat or 
human) species [19-21]. Within the conserved omain of the 
PDE3s is an insertion of 44 amino acids which is not present 
in the conserved omains of other PDE families [19-21]. The 
N-terminal regulatory domain contains everal consensus sites 
for cAMP-dependent protein kinase phosphorylation a d hy- 
drophobic putative membrane association domains [19-21]. 
Although there is considerable information regarding PDE3 
in normal tissue, little is known of its presence in tumors. 
Recent in situ hybridization studies have indicated that rat 
cGIP1 mRNA is expressed in liver parenchymal cells, whereas 
rat cGIP2 mRNA is found in vascular elements [22]. In this 
study we observed ifferential expression of the two PDE3 
mRNAs in several human hepatoma cell lines. Whether these 
findings reflect the ontological lineage of these tumor cell lines 
and/or a role for PDE3 in carcinogenesis remains to be estab- 
lished. 
2. Materials and methods 
2.1. Cell lines 
Human hepatoma HepG2 cells, established from a human hepato- 
blastoma [23], were maintained in RPMI-1640 containing 10% fetal 
bovine serum. Human hepatoma cell lines Hep3B and HUH7, estab- 
lished from well-differentiated hepatocellular carcinomas, and SK- 
Hep-1 from hepatic adenocarcinoma, were maintained in Eagle's 
minimal essential medium containing 10% fetal bovine serum and 
1% nonessential mino acids [23-26]. Media were changed every 
2 days. 
2.2. PDE activity in cell extracts 
Cultures were initiated with 1 x 106 HepG2 cells/10 cm diameter 
plate (Falcon Plastics) and Hep3B, HuH7 and SK-Hep-1 cells, at 
0.5x 106 cells/10 cm plate. After 5 days, cells were washed twice 
with phosphate-buffered saline (PBS), harvested with a rubber police- 
man, homogenized in 2 ml of ice-cold STS buffer [10 mM TES (pH 
7.0), 250 mM sucrose, 10 ~tg/ml (each) of pepstatin and leupeptin, 
5 ~tg/ml aprotinin, 3 mM benzamidine, 0.2 mM PMSF, 13 mM I~- 
mercaptoethanol, 0.2mM EDTA, 1 mM MgC12] and centrifuged 
(100 000 x g, 45 min, 4°C) to obtain crude particulate and supernatant 
fractions. Particulate fractions were suspended in 1 ml of STS buffer. 
2.3. cAMP PDE assay 
cAMP-PDE activity was assayed by a modification of a published 
procedure [13]. Samples were incubated at 30°C for 10 min in a total 
volume of 0.3 ml containing 50 mM HEPES (pH 7.4), 0.1 mM 
EDTA, 8.3 mM MgCI2, 0.1 txM [3H]cAMP (18000 cpm). PDE3 ac- 
tivity (pmol cAMP hydrolyzed per min) was measured as cAMP hy- 
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drolysis that was inhibited by 0.5 ~tM OPC 3689, a specific inhibitor 
of PDE3s [1]. 
2.4. RNA isolation 
Total RNA was isolated from human adipose tissue and hepatoma 
cells [37] and poly(A) + RNA was prepared using the Promega mRNA 
isolation system. Poly(A) + RNA from human heart and liver was 
purchased from Clontech. 
2.5. Northern blots 
To amplify the HcGIP1 cDNA probe (corresponding to nt 883- 
3339; Taira et al., unpublished ata), oligonucleotide s nse (5'-(TCC 
AGC TGC GTG TCG TTA GGA, corresponding tont 883-903) and 
antisense (5'-CCG CTC GAG TCT AGA CTA TTC CTC TTC ATC 
TGC CT, corresponding to nt 3320-3339 with XhoI and XbaI sites 
underlined, respectively) PCR primers based on the nucleic acid se- 
quence of HcGIP1 were synthesized on an Applied Biosystems 380B 
DNA synthesizer. To amplify the HcGIP2 cDNA probe (correspond- 
ing to nt 1837-3426 [20]), oligonucleotide sense (5'-CGA TGG 
GGA TCC AGT CGA ACA GAT GAC ACT GC, corresponding 
to nt 1837-1856 with BamHI site) and antisense (5'-CAT 
GGA ATT CGA TCA CTG GTC TGG CTT TTG GGT, corre- 
sponding to nt 34063426 with EcoRI site) PCR primers were synthe- 
sized. 
PCR amplification was carried out in a total volume of 50 ~tl 
(HcGIP1) or 100 ~tl (HcGIP2) containing 20 mM Tris-HCl (pH 
8.2), 10 mM KC1, 6 mM (NH4)S04, 2 mM MgC12, 200 ~tM dNTPs, 
0.1% Triton X-100, 10 p.g/ml nuclease-free BSA and 2.5 units 
(HcGIP1) or 1 unit (HcGIP2) Pfu DNA polymerase (Stratagene) 
with 500 ng (HcGIP1) or 20 ng (HcGIP2) of template and 0.6 laM 
(HcGIP1) or 0.1 laM (HcGIP2) sense and antisense primers. PCR was 
performed under conditions of denaturing at 94°C for 15 s, annealing 
at 66°C for 30 s (two cycles), 64°C for 30 s (two cycles), 62°C for 30 s 
(two cycles), 60°C for 30 s (two cycles) for the first eight cycles and at 
58°C for 30 s for the next 28 cycles and extension for each cycle at 
72°C for 2 min 30 s, and with final extension at 72°C for 10 rain. PCR 
products were purified using QIAEX (Qiagen) after electrophoresis in 
1% agarose gel (50 V, 90 min). 
For Northern blots, samples (~2.5 I.tg) of poly(A) + RNA in for- 
maldehyde/formamide/MOPS were incubated at 65°C for 15 rain and 
then subjected to electrophoresis in 1% agarose/formaldehyde gels(25 
V, 19 h). Gels were stained with ethidium bromide, and mRNA was 
transferred to nylon membranes (Schleicher and Schuell) and fixed 
using a UV crosslinker (Stratalinker, Stratagene). Blots were prehy- 
bridized at 65°C in 5 x SSC, 0.5% SDS, 2.5 X Denhardt's solution, 200 
~tg/ml salmon sperm DNA, 20 mM Tris and hybridized at 65°C over- 
night with fresh solution containing 32P-labeled HcGIP1 (883 3339) 
and HcGIP2 (1837-3426) probes (random priming kit, Stratagene). 
Following a wash at room temperature in 2 x SSC/0.1% SDS, blots 
were washed at 65°C for 20 min with 1.0 X SSC/0.1% SDS, for 20 min 
with 0.5 x SSC/0.1% SSC, and then for 20 min with 0.2x SSC/0.1% 
SSC. Films were exposed for 5 days at -70°C with an intensifying 
screen. The blots shown in Fig. 3 were reprobed with 32P-labeled 
HepG2 Hcp,3B HuIt7 
Fig. 1. Effect of inhibitors on PDE activity in hepatoma cells. 
Homogenates were prepared from hepatoma cell lines and assayed 
for PDE activity with or without inhibitors as described in Section 
2. Data are mean _+ S.E.M. of three experiments. 
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Fig. 2. Distribution of specific cGI PDE activity in hepatoma cells. 
Particulate (P) and supernatant (S) fractions were prepared from he- 
patoma cells and assayed for PDE3 activity with or without 0.5 IxM 
OPC 3689 as described in Section 2. Numbers in parentheses repre- 
sent total activity in particulate and supernatant fractions (pmol/min 
per dish). Data are mean + S.E.M. of three experiments. 
human 6-actin (Clontech). Labeling, hybridization, and washing con- 
ditions were as described above. 
3. Results and discussion 
PDE3s are very sensitive to inhibition by a number of in- 
otropic and antithrombotic agents, including cilostamide and 
other OPC (Otsuka Pharmaceutical Co.) derivatives, imazo- 
dan, milrinone, enoximone, LY195115 [1,3,6,14,19]. cGMP is 
a competitive inhibitor of cAMP hydrolysis by PDE3 [6-14]. 
Inhibition of cAMP hydrolysis by cGMP also distinguishes 
PDE3s (cGI PDE) from PDE4s (cAMP-specific PDE) which 
exhibit a 'low Km' for cAMP and are inhibited by rolipram 
but not by cGMP [1]. As shown in Fig. 1, in extracts of 
HepG2, Hep3B and HuH7 cells, PDE activity was inhibited 
by OPC 3689, cGMP and rolipram, indicating the presence of 
both PDE3 and PDE4 enzymes. In SK-Hep-1, the PDE activ- 
ity was only slightly inhibited by OPC 3689 and rolipram, but 
was strongly inhibited by 5 ~tM cGMP (Table 1). It is very 
likely that this cGMP-inhibited activity reflects a PDE1 (cal- 
modulin-sensitive PDE) since cAMP hydrolysis in SK-Hep-1 
homogenates was inhibited by 0.1 mM EGTA plus 2 mM 
EDTA, activated by Ca and calmodulin, and the calmodu- 
lin-stimulated activity inhibited by cGMP (Table 1). Thus, in 
constrast o HepG2, Hep3B and HuH7 cells (Fig. 1) in which 
PDE3 and PDE4 are major contributors to hydrolysis of 
cAMP, these two PDEs hydrolyze little or no cAMP in ex- 
tracts from SK-Hepl adenocarcinomas in which a calmodu- 
lin-sensitive PDE is apparently a major PDE isoform (Table 
1). 
The apparent subcellular localization of PDE3s differs in 
different cells [6]. Most of the platelet PDE3 is cytosolic 
[12,13,27,28], whereas in adipocytes and hepatocytes, PDE3 
activity is predominantly particulate [2,6,7,9,10,29,30] and in 
heart, both particulate and cytosolic [31-34]. In HepG2 and 
Hep3B most of the PDE3 activity was in the particulate frac- 
tion, but in HuH7 30% of PDE3 activity was in the super- 
natant fractions (Fig. 2). 
cGIP1 mRNAs are relatively highly expressed in rat and 
3T3-L1 adipocytes and human adipose tissue and cGIP2 
mRNAs are expressed in rat heart, rat aorta, rat and human 
adipose tissue, human heart and human aorta [19-22]. It is 
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Fig. 3. Northern blots hybridized with (A) HcGIP1 or (B) HcGIP2 cDNA probes. Total RNA was prepared from the indicated tissues [37]; 
poly(A) + RNA (2.5 ktg) was purchased or prepared, applied to each lane, subjected to electrophoresis in a 1% agarose-formaldehyde gel, and 
transferred to a nylon membrane as described in Section 2. Blots were prehybridized at 65°C, hybridized at 65°C overnight with 32p-labeled 
cDNA (the HcGIP1 probe, nt 883-3339, or HcGIP2, nt 1837-3426), and washed as described in Section 2. Films were exposed for 5 days at 
-70°C with an intensifying screen. The same blots were reprobed with 32p-labeled human 6-actin cDNA (Clontech). 
likely that the RcGIP2 mRNA in adipose tissue reflects the 
presence of vascular elements, since RcGIP2 cDNA hybri- 
dized weakly, if at all, to mRNA from isolated rat fat cells 
or differentiated murine 3T3-L1 adipocytes [21] and in situ 
hybridization experiments also indicated that RcGIP1 
mRNA is abundant  in fat cells and RcGIP2 mRNA in vas- 
cular smooth muscle [22]. 
HcGIP1 cDNA hybridized much more strongly with 
Table 1 
Type I Ca~+/calmodulin sensitive PDE activity in SK-Hep-1 cells 
Additions cAMP hydrolysis (pmol/min per mg protein) 
- cGMP +cGMP (5 laM) 
None 
OPC 3689 (0.5 IxM) 
Rolipram (25 IxM) 
EGTA (0.1 mM), EDTA (2 mM) 
EGTA, EDTA, Ca 2+ (2 mM) 
EGTA, EDTA, Ca 2+, calmodulin (0.1 ~tg) 
208 + 10.9 22 + 5.6 
205 + 8.2 
200 + 28.9 
151 + 15.9 19+ 3.5 
203 + 17.4 56 + 9.7 
430 + 26.8 44 + 3.5 
Homogenates from SK-Hep-1 cells were assayed in duplicate for cAMP PDE activity with and without cGMP and the indicated additions as 
described in Section 2. Values represent mean + S.E.M. (n=3). 
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poly(A) + RNA species of 6.4 and 5.4 kb from Hep3B, HepG2 
and adipose tissue than from HuH7 and liver (Fig. 3). 
HcGIP1 hybridized weakly with mRNA from HUH7, and 
little, if at all, with mRNA from heart or SK-Hep-1 (Fig. 
3). On the other hand, HcGIP2 cDNA hybridized with poly(- 
A) + RNA species of 8.4 and 7.2 kb from heart and adipose 
tissue. HcGIP2 cDNA hybridized with ~ 7.2-kb mRNA from 
Hep3B and HUH7. HcGIP2 cDNA did not apparently hybri- 
dize strongly with mRNA from HepG2 and SK-Hep-1 (Fig. 
3). Thus, neither PDE3 mRNA, i.e. HcGIP1, nor HcGIP2 
mRNA was apparently detected in SK-Hep-1 cells, consistent 
with the lack of inhibition of SK-Hep-1 PDE activity with 
cilostamide (Table 1). There have been no other reports of 
cGIP1 and cGIP2 mRNAs expressed in single cell populations 
as they seem to be in Hep3B and HuH7 cells. It will be of 
interest to determine which PDE4 isoforms are present in 
HepG2, Hep3B and HuH7 cells. 
The additional region in the conserved catalytic domain of 
PDE3 does not correspond to sequences within the conserved 
domains of other PDE families [19-21]. Using degenerate pri- 
mers from both sides of this additional region in the con- 
served catalytic domain of PDE3, which could amplify either 
HcGIP1 or HcGIP2 cDNAs, a ,-~ 300-bp fragment was iso- 
lated by RT-PCR cloning from HepG2 RNA (data not 
shown); its nucleotide sequence was identical to the corre- 
sponding region in the conserved omain of HcGIP1, consist- 
ent with the finding that the HcGIP1 cDNA probe hybridized 
strongly and the HcGIP2 cDNA probe weakly, if at all, to 
HepG2 mRNA (Fig. 3). 
Based on inhibition of cAMP hydrolysis by cilostamide and 
cGMP and on Northern blot hybridizations, PDE3s were 
present in hepatoblastoma (HepG2)-and hepatocellular 
(Hep3B and HuH7)-derived cells and little, if at all, in cells 
derived from an adenocarcinoma (SK-Hep-1). HcGIP2 
mRNA was detected in hepatocellular tumor cells (Hep3B 
and HUH7) but not (or in much lower amounts) in the hepa- 
toblastoma-derived HepG2 cells, whereas HcGIP1 mRNA 
was found in all three hepatoma cell lines. Whether one or 
both PDE3 isoforms plays a role in the development or dif- 
ferentiation of hepatocellular carcinomas or hepatoblastoma 
(as opposed to hepatic adenocarcinomas) remains to be estab- 
lished. 
Although our results are limited to a small number of cell 
lines, knowledge of specific PDE isoenzyme gene family mem- 
bers in specific tumor cells might be important in designing 
therapy to inhibit tumor cell growth. It is known that cAMP 
and cAMP analogs produce antiproliferative effects in various 
human cancer cell lines [35,36], in some cases perhaps by 
altering expression of RI and RII regulatory subunits of 
cAMP-dependent protein kinases [35]. Identification of the 
PDE types in tumor cells might allow use of specific inhibitors 
(e.g. compounds analogous to milrinone and cilostamide for 
PDE3 or to rolipram for PDE4) as adjunct herapeutic agents 
to potentiate the responses to cAMP analogs. This conceptual 
approach might be relevant, since it has been reported that 
low (gM) concentrations of 8-CI-cAMP, which inhibit cell 
growth of a number of human cancer cell lines, were hydro- 
lyzed by PDE3 at 30% of the efficiency of cAMP [36]. Several 
studies have in fact reported synergistic interactions between 
specific PDE3 inhibitors (cilostamide [18], CI-930 [15,18], 
SKF94836 [16] and milrinone [17]) and specific PDE4 inhibi- 
tors (Ro 20-1724, rolipram [16-18]) in attenuation of DNA 
synthesis and proliferation of rat [18] and porcine vascular 
smooth muscle cells [16] and rat [17] and human T-lympho- 
cytes [15]. 
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